NASDAQ:ATXS Astria Therapeutics (ATXS) Stock Price, News & Analysis $5.17 -0.04 (-0.77%) Closing price 04:00 PM EasternExtended Trading$5.18 +0.00 (+0.10%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Astria Therapeutics Stock (NASDAQ:ATXS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Astria Therapeutics alerts:Sign Up Key Stats Today's Range$4.97▼$5.3550-Day Range$3.75▼$7.1452-Week Range$3.56▼$12.92Volume292,646 shsAverage Volume377,761 shsMarket Capitalization$291.76 millionP/E RatioN/ADividend YieldN/APrice Target$26.60Consensus RatingBuy Company OverviewAstria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.Read More… Astria Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks46th Percentile Overall ScoreATXS MarketRank™: Astria Therapeutics scored higher than 46% of companies evaluated by MarketBeat, and ranked 638th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingAstria Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.29, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAstria Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Astria Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Astria Therapeutics are expected to decrease in the coming year, from ($1.65) to ($1.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Astria Therapeutics is -2.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Astria Therapeutics is -2.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAstria Therapeutics has a P/B Ratio of 1.55. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Astria Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.16% of the float of Astria Therapeutics has been sold short.Short Interest Ratio / Days to CoverAstria Therapeutics has a short interest ratio ("days to cover") of 9.7.Change versus previous monthShort interest in Astria Therapeutics has recently decreased by 10.34%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAstria Therapeutics does not currently pay a dividend.Dividend GrowthAstria Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.16% of the float of Astria Therapeutics has been sold short.Short Interest Ratio / Days to CoverAstria Therapeutics has a short interest ratio ("days to cover") of 9.7.Change versus previous monthShort interest in Astria Therapeutics has recently decreased by 10.34%, indicating that investor sentiment is improving significantly. News and Social Media2.6 / 5News Sentiment1.66 News SentimentAstria Therapeutics has a news sentiment score of 1.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Astria Therapeutics this week, compared to 2 articles on an average week. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Astria Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.90% of the stock of Astria Therapeutics is held by insiders.Percentage Held by Institutions98.98% of the stock of Astria Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Astria Therapeutics' insider trading history. Receive ATXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Astria Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ATXS Stock News HeadlinesAstria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 2, 2025 | businesswire.comAstria Therapeutics price target raised to $28 from $27 at WedbushMarch 12, 2025 | markets.businessinsider.comTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly that, just 12 months later…April 25, 2025 | Paradigm Press (Ad)Wedbush Keeps Their Buy Rating on Astria Therapeutics (ATXS)March 12, 2025 | markets.businessinsider.comAstria Therapeutics (ATXS) Gets a Buy from WedbushMarch 12, 2025 | markets.businessinsider.comAstria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 4, 2025 | businesswire.comTD Cowen Remains a Buy on Astria Therapeutics (ATXS)March 1, 2025 | markets.businessinsider.comAstria Therapeutics Initiates ALPHA-ORBIT Phase 3 Pivotal Trial of Navenibart in Hereditary AngioedemaFebruary 27, 2025 | businesswire.comSee More Headlines ATXS Stock Analysis - Frequently Asked Questions How have ATXS shares performed this year? Astria Therapeutics' stock was trading at $8.94 at the beginning of 2025. Since then, ATXS stock has decreased by 42.2% and is now trading at $5.17. View the best growth stocks for 2025 here. How were Astria Therapeutics' earnings last quarter? Astria Therapeutics, Inc. (NASDAQ:ATXS) posted its quarterly earnings results on Tuesday, March, 11th. The biotechnology company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.01. When did Astria Therapeutics' stock split? Astria Therapeutics shares reverse split before market open on Friday, August 20th 2021. The 1-6 reverse split was announced on Friday, August 20th 2021. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 20th 2021. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split. Who are Astria Therapeutics' major shareholders? Top institutional investors of Astria Therapeutics include GAMMA Investing LLC (0.02%). View institutional ownership trends. How do I buy shares of Astria Therapeutics? Shares of ATXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Astria Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Astria Therapeutics investors own include CRISPR Therapeutics (CRSP), Voyager Therapeutics (VYGR), Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH), The RMR Group (RMR) and AUO (AUOTY). Company Calendar Last Earnings3/11/2025Today4/25/2025Next Earnings (Estimated)5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ATXS CIK1454789 Webwww.catabasis.com Phone(617) 349-1971Fax617-273-2637Employees30Year Founded2008Price Target and Rating Average Stock Price Target$26.60 High Stock Price Target$35.00 Low Stock Price Target$16.00 Potential Upside/Downside+414.5%Consensus RatingBuy Rating Score (0-4)3.29 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-72,890,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-43.58% Return on Assets-29.36% Debt Debt-to-Equity RatioN/A Current Ratio22.38 Quick Ratio22.38 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.33 per share Price / Book1.55Miscellaneous Outstanding Shares56,434,000Free Float54,797,000Market Cap$291.76 million OptionableOptionable Beta0.68 Social Links 10 Stocks Set to Soar in Spring 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:ATXS) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Astria Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Astria Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.